Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts

Experimental Biology and Medicine

Volumn 233, Issue 1, 2008, Pages 76-83

  Ramond, Amandine ^a,b   Sartorius, Eugénie ^a,b   Mousseau, Mireille ^c   Ribuot, Christophe ^a,b   Joyeux Faure, Marie ^a,b,d  

^a Domaine de la Merci   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

Cardiotoxicity; Doxorubicin; Erythropoietin; Isolated rat heart; Trastuzumab

Indexed keywords

DOXORUBICIN; RECOMBINANT ERYTHROPOIETIN; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; ISOLATED HEART; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; DOXORUBICIN; ERYTHROPOIETIN, RECOMBINANT; HEART; PROTECTIVE AGENTS; RATS; VENTRICULAR FIBRILLATION;

RATTUS;

EID: 37549028426     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0706-RM-152     Document Type: Article

References (54)

1. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 33:2-14, 2006.
2. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 65:823-832, 1978.
3. Singer JW, Narahara KA, Ritchie JL, Hamilton GW, Kennedy JW. Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep 62:945-948, 1978.
4. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, Cohen H, Jaffe N. Congestive heart failure due to Adriamycin cardiotoxicity: its natural history in children. Cancer 47:2810-2816, 1981.
5. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709-718, 1981.
6. Taylor AL, Bulkley BH. Acute Adriamycin cardiotoxicity: morphologic alterations in isolated perfused rabbit heart. Lab Invest 47:459-464, 1982.
7. Pelikan PC, Weisfeldt ML, Jacobus WE, Miceli MV, Bulkley BH, Gerstenblith G. J Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. Cardiovasc Pharmacol 8:1058-1066, 1986.
8. Cargill C, Bachmann E, Zbinden G. Effects of daunomycin and anthramycin on electrocardiogram and mitochondrial metabolism of the rat heart. J Natl Cancer Inst 53:481-486, 1974.
9. Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 30:292-304, 1974.
10. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37:2705-2713, 1977.
11. Olson HM, Capen CC. Subacute cardiotoxicity of Adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest 37:386-394, 1977.
12. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1977.
13. Dalloz F, Maingon P, Cottin Y, Briot F, Horiot JC, Rochette L. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med 26:785-800, 1999.
14. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65:128-135, 1980.
15. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38:1745-1750, 1978.
16. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 2:487-515, 1980.
17. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 5:913-919, 1983.
18. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983.
19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
20. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
22. Routledge HC, Rea DW, Steeds RP. Monitoring the introduction of new drugs - Herceptin to cardiotoxicity. Clin Med 6:478-481, 2006.
23. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 29:22-28, 2002.
24. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 81:2223-2236, 1993.
25. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18:1031-1033, 2004.
26. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63:208-216, 2004.
27. Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 19:439-446, 2005.
28. Joyeux-Faure M, Ramond A, Beguin PC, Belaidi E, Godin-Ribuot D, Ribuot C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 20:51-56, 2006.
29. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 42:233-241, 2005.
30. Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G, George J. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27:1876-1883, 2006.
31. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, Minatoguchi S, Fujiwara T, Fujiwara H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113:535-543, 2006.
32. Lambert C, Mossiat C, Tanniere-Zeller M, Maupoil V, Rochette L. Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts. Cardiovasc Res 24:653-658, 1990.
33. Joyeux M, Godin-Ribuot D, Faure P, Demenge P, Ribuot C. Heat stress protects against electrophysiological damages induced by acute doxorubicin exposure in isolated rat hearts. Cardiovasc Drugs Ther 15:219-224, 2001.
34. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 289:R424-R431, 2005.
35. Leyland-Jones B. Dose scheduling - Herceptin. Oncology 61(Suppl 2):31-36, 2001.
36. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riermersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 22:447-455, 1988.
37. Pye MP, Cobbe SM. Arrhythmogenesis in experimental models of heart failure: the role of increased load. Cardiovasc Res 32:248-257, 1996.
38. Monti E, Cova D, Guido E, Morelli R, Oliva C. Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med 21:463-470, 1996.
39. Morishima I, Matsui H, Mukawa H, Hayashi K, Toki Y, Okumura K, Ito T, Hayakawa T. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci 63:511-521, 1998.
40. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124:425-427, 1998.
41. Balli E, Mete UO, Tuli A, Tap O, Kaya M. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopathol 19:1101-1108, 2004.
42. Deres P, Halmosi R, Toth A, Kovacs K, Palfi A, Habon T, Czopf L, Kalai T, Hideg K, Sumegi B, Toth K. Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J Cardiovasc Pharmacol 45:36-43, 2005.
43. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473-479, 2004.
44. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79-85, 2003.
45. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-4806, 2003.
46. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100:11612-11617, 2003.
47. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007, 2003.
48. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71:684-694, 2006.
49. Hirata A, Minamino T, Asanuma H, Sanada S, Fujita M, Tsukamoto O, Wakeno M, Myoishi M, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Tomoike H, Hori M, Kitakaze M. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19:33-40, 2005.
50. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapy in breast cancer: the HER-2/neu gene and protein, Mol Cell Proteomics 3:379-398, 2004.
51. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12, 2004.
52. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-10269, 1998.
53. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for Herceptin-induced cardiomyopathy. J Am Coll Cardiol 44:2231-2238, 2004.
54. Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, Holtz J. Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J Mol Cell Cardiol 38:485-493, 2005.